315 related articles for article (PubMed ID: 9664143)
1. Effects of oncostatin M and tamoxifen on human melanoma cells.
Gibbs P; Chen Q; Robinson WA
Melanoma Res; 1998 Jun; 8(3):221-6. PubMed ID: 9664143
[TBL] [Abstract][Full Text] [Related]
2. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
Lu C; Rak JW; Kobayashi H; Kerbel RS
Cancer Res; 1993 Jun; 53(12):2708-11. PubMed ID: 8504408
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
4. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
5. The influence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo findings.
Puchner MJ; Köppen JA; Zapf S; Knabbe C; Westphal M
Anticancer Res; 2002; 22(1A):45-51. PubMed ID: 12017331
[TBL] [Abstract][Full Text] [Related]
6. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M is a differentiation factor for myeloid leukemia cells.
Bruce AG; Hoggatt IH; Rose TM
J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
[TBL] [Abstract][Full Text] [Related]
8. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M induces the differentiation of breast cancer cells.
Douglas AM; Grant SL; Goss GA; Clouston DR; Sutherland RL; Begley CG
Int J Cancer; 1998 Jan; 75(1):64-73. PubMed ID: 9426692
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases.
Chen SH; Gillespie GY; Benveniste EN
Glia; 2006 Jan; 53(2):191-200. PubMed ID: 16206166
[TBL] [Abstract][Full Text] [Related]
12. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.
Lacreusette A; Barbieux I; Nguyen JM; Pandolfino MC; Dréno B; Jacques Y; Godard A; Blanchard F
J Pathol; 2009 Apr; 217(5):665-76. PubMed ID: 19097071
[TBL] [Abstract][Full Text] [Related]
13. The oncostatin M signalling pathway: reversing the neoplastic phenotype?
Grant SL; Begley CG
Mol Med Today; 1999 Sep; 5(9):406-12. PubMed ID: 10462753
[TBL] [Abstract][Full Text] [Related]
14. Modulation of LIF expression in human melanoma cells by oncostatin M.
Heymann D; Blanchard F; Raher S; De Groote D; Godard A
Immunol Lett; 1995 Jun; 46(3):245-51. PubMed ID: 7590943
[TBL] [Abstract][Full Text] [Related]
15. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
[TBL] [Abstract][Full Text] [Related]
17. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide.
Repovic P; Mi K; Benveniste EN
Glia; 2003 Jun; 42(4):433-46. PubMed ID: 12730964
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S; Ugolini D; Palumbo R
Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
